Bortezomib a safety treatment for patients with Multiple Myeloma and Cystic Fibrosis
<p><strong>Introduction: </strong>Bortezomib is a proteasome inhibitor that targets myeloma cell and its bone marrow micro-environment. Intravenous Bortezomib (1.3 mg/m<sup>2</sup> administered on days 1,4,8 and 11 of a 21 day cycle), with or without dexamethasone, is e...
Збережено в:
| Автори: | , , , , , |
|---|---|
| Формат: | Artigo |
| Мова: | Inglês |
| Опубліковано: |
PAGEPress Publications
2012-01-01
|
| Серія: | Mediterranean Journal of Hematology and Infectious Diseases |
| Предмети: | |
| Онлайн доступ: | http://www.mjhid.org/article/view/10316 |
| Теги: |
Немає тегів, Будьте першим, хто поставить тег для цього запису!
|